Abstract
Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation from HLA-mismatched family donors. All patients achieved sustained myeloid engraftment. The cumulative incidence of grades II–IV acute GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15%. The 2-year cumulative incidence of chronic GVHD was 56%. After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive. The 2-year probability of leukemia-free survival (LFS) was 65%. Patients transplanted within 7 months of diagnosis had better LFS (89 vs 43% ). Severe aGVHD decreased the LFS significantly by increasing non-relapse mortality (NRM). This study confirms that HLA-mismatched HSCT is a treatment option for MDS. Patients with high-risk MDS benefit from receiving HSCT early in the course of the disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fukumoto JS, Greenber PL . Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2005; 56: 179–192.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297.
Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40: 444–455.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. The French-American-British(FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.
Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myeodyaplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. LARC Press: Lyon, 2001. pp 61–73.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood 1997; 89: 2079–2088.
Martin P, Nash R, Sanders J, Leisenring W, Anasetti C, Deeg HJ et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplantation 1998; 92: 2303–2314.
Sullivan KM . Graft-versus-host-disease. In Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, MA, 1999, 515–536.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 414–417.
Elfenbein GJ, Sackatein R . Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 2: 27–339.
Huang XJ, Chang YJ, Zhao XY . A direct comparison of immunological characteristics of granulocyte-colony stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Hematologica 2005; 90: 715–716.
Huang XJ, Chang YJ, Zhao XY . Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193–197.
Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997–2004.
Mattijssen V, Schattenberg A, Schaap N, Preijers F, De Witte T . Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 1997; 19: 791–794.
Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 255–261.
de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2000; 110: 620–630.
Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943–1951.
de Witte T, Pikkemaat F, Hermans J, van Biezen A, Mackinnan S, Cornelissen J et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 2001; 15: 1878–1884.
Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370–4378.
Zhao XY, Chang YJ, Huang XJ . Effects of rhG-CSF mobilization on immunological properties of grafts from peripheral blood and bone marrow. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 787–790.
Huang XJ, Chang YJ, Zhao XY . Hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193–197.
Martino R, van Biezen A, Iacobelli S, Brand R, Niederwieser DW, de Witte T . Reduced-intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings in adults with myelodysplastic syndrome (MDS). A comparison with standard myeloablative conditioning: a study of the EBMT-Chronic Leukemia Working Party (EBMT-CLWP). Abstracts for the 45th annual meeting of the American Society of Hematology. Blood 2003; 102: 184a.
Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for myelodysplastic syndromes with advanced disease morphology: a phase II study of bsulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220–226.
Xu LP, Huang XJ, Liu KY, Chen H, Liu DH, Han W et al. Allogeneic stem cell transplantation from genotypically HLA-identical siblings for 30 patients with myelodysplastic syndromes. zhonghua Xue Ye Xue Za Zhi 2006; 27: 518–520.
Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19: 396–401.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201–1207.
Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ . Pretransplantation in induction chemotherapy and postrransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 65–73.
CIBMTR Newsletter July 2008. http://www.cibmtr.org/PUBLICATIONS/Newsletter/DOCS/2008Jul.pdf.
Acknowledgements
This work was supported by the Key Projects in the National Science & Technology Pillar Program in the Eleventh Five-year Plan Period (Grant No. 2008BAI61B02), the National Science Foundation for Distinguished Young Scholars of China (No. 30725038) and Innovation team by the Ministry of Education (No. IRT0702).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chen, Y., Liu, K., Xu, L. et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Bone Marrow Transplant 45, 1333–1339 (2010). https://doi.org/10.1038/bmt.2009.351
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.351
Keywords
This article is cited by
-
Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation
Bone Marrow Transplantation (2023)
-
The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen
Annals of Hematology (2021)
-
The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology
Journal of Hematology & Oncology (2018)
-
Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients
Bone Marrow Transplantation (2018)
-
Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant
Leukemia (2016)